Holen Sie sich die Stockscreener-App
2.56
8.94%
0.21
Handel nachbörslich:
2.53
-0.03
-1.17%
Schlusskurs vom Vortag:
$2.35
Offen:
$2.57
24-Stunden-Volumen:
1.24M
Relative Volume:
1.09
Marktkapitalisierung:
$7.87M
Einnahmen:
$2.45M
Nettoeinkommen (Verlust:
$-5.47M
KGV:
-
EPS:
-
Netto-Cashflow:
$-6.05M
1W Leistung:
+11.79%
1M Leistung:
-40.19%
6M Leistung:
-97.83%
1J Leistung:
-99.34%
1-Tages-Spanne:
$2.08
$2.70
1-Wochen-Bereich:
$1.86
$3.56
52-Wochen-Spanne:
$1.7402
$778.00
Elevai Labs Inc Stock (ELAB) Company Profile
Firmenname
Elevai Labs Inc
Sektor
Branche
Telefon
18667944940
Adresse
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie ELAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAB
Elevai Labs Inc
|
2.56 | 7.87M | 2.45M | -5.47M | -6.05M | -59.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevai Labs Inc Aktie (ELAB) Neueste Nachrichten
Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada - Yahoo Finance
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada - GlobeNewswire
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada - The Manila Times
Elevai Labs announces withdrawal of offer to exchange - MSN
Elevai Biosciences gears up for FDA talks on obesity drug By Investing.com - Investing.com Canada
Elevai Biosciences Announces FDA Regulatory Pathway for EL-22 - Marketscreener.com
Elevai Biosciences gears up for FDA talks on obesity drug - Investing.com India
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - The Manila Times
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai's Novel Obesity Drug EL-22 Advances Toward FDA Review, Targets Muscle Preservation Breakthrough - StockTitan
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market - The Manila Times
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches - GlobeNewswire
Elevai Labs Disrupts Hair Care Market with AI-Powered Root Renewal System Launch | ELAB Stock News - StockTitan
Data-Based Insights About Elevai Labs Inc (ELAB) - Stocks Register
ELABElevai Labs, Inc. Latest Stock News & Market Updates - StockTitan
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division - The Manila Times
Elevai Labs Hits Record $300K Monthly Revenue, Surges 65% After Strategic Overhaul - StockTitan
Elevai Labs Inc. announced that it expects to receive $1 million in funding - Marketscreener.com
Elevai Labs Inc. Announces Executive Changes - Marketscreener.com
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology - Marketscreener.com
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com
Elevai Labs Inc. Announces Management Changes - Marketscreener.com
Elevai Labs Inc. Announces Resignation of Hatem Abou-Sayed MD as Member of the Board of Directors and as Chief Medical Officer - Marketscreener.com
Elevai Labs, Inc. Enters into Licensing Agreement with Yuva Biosciences, Inc. to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products - Marketscreener.com
Elevai Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Elevai Labs announces 1-for-200 reverse stock split - Investing.com
Elevai Labs announces 1-for-200 reverse stock split By Investing.com - Investing.com Canada
ELEVAI Labs Inc trading halted, news pending - TipRanks
Elevai Labs Inc. adjusts shareholder meeting quorum By Investing.com - Investing.com Nigeria
Elevai Labs Inc. adjusts shareholder meeting quorum - Investing.com
Elevai Labs stock plunges to 52-week low of $0.02 By Investing.com - Investing.com South Africa
Elevai Labs stock plunges to 52-week low of $0.02 - Investing.com
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - GlobeNewswire
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - The Manila Times
Elevai Labs Announces 1-for-200 Reverse Split to Maintain Nasdaq Listing | ELAB Stock News - StockTitan
Elevai Labs Withdraws Stock Exchange Offer Due to DTC Technical Issues | ELAB Stock News - StockTitan
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) - Simply Wall St
CORRECTIONElevai Labs Inc. - The Bakersfield Californian
Elevai Labs Reports Mixed Q3: 74.7% Margins, Revenue Dips 4.9% Amid $8M Offering | ELAB Stock News - StockTitan
Elevai Labs Inc (ELAB) Quarterly 10-Q Report - Quartzy
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewswire
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Elevai Labs granted extension to meet Nasdaq listing standards - Investing.com
Elevai Labs granted extension to meet Nasdaq listing standards By Investing.com - Investing.com Canada
Natural Gas (NGN23) Quote - The Globe and Mail
Carebook Technologies Inc (CRBKF) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amidst Biotech Sector Volatility - GuruFocus.com
Elevai Labs announces update and extension of pending offer to exchange shares of common stock - MSN
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Finanzdaten der Elevai Labs Inc-Aktie (ELAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):